ArticleRevista medica del Instituto Mexicano del Seguro Social2024
[Predictive factors for MASLD in type 2 diabetes: 1 year follow-up study].
Article in Revista medica del Instituto Mexicano del Seguro Social, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- [Metabolic Dysfunction-Associated Steatotic Liver Disease and its association with prediabetes in adolescents with obesity].Revista medica del Instituto Mexicano del Seguro Social · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: It has been proposed the current nomenclature for metabolic dysfunction-associated steatotic liver disease (MASLD) as a general term to encompass the various etiologies of steatosis and to include the presence of at least 1 of 5 cardiometabolic risk factors. Objective: To evaluate the predictors of the incidence of MASLD in patients with type 2 diabetes (T2D) in primary care at a one-year follow-up. Material and methods: Prospective cohort study including patients (n = 5143) with ≤ 15 years from diagnosis of T2D, treated at primary care units in Mexico City and metropolitan area. At baseline and at one-year follow-up were measured: anthropometry, HbA1c, microalbuminuria, creatinine, lipid profile and hepatic markers aspartate aminotransferase and alanine aminotransferase (ALT). Hepatic Steatosis Index (HSI) and Lipidic Accumulation Product (LAP) were calculated. MASLD was considered as cases with abnormal ALT. Results: At baseline, 1449 (28.2%) patients presented MASLD. The HSI and LAP indices were higher in MASLD. Age at diagnosis and time of exposure to T2D were inversely associated with MASLD, and directly proportional to body mass index, waist circumference (WC) and HbA1c. Of the cases with MASLD at baseline, 452 (38.8%) reverted to normal and 712 (61.2%) persisted after follow-up. ORs for MASLD were 1.86 and 1.88 for HbA1c and WC, respectively. Conclusions: The combination of HSI, LAP and screening with HbA1c and WC are useful to identify MASLD in patients with T2D.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.